Vikas Gupta, MD, PhD

One star
One star
One star
One star
One star

Rating: 5 out of 5 (199 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2015

Call 404-778-1900

Background

A board certified hematologist and medical oncologist, Vikas A. Gupta, MD, PhD, joined the clinical staff at Winship Cancer Institute as a practicing physician in September 2015. Dr. Gupta is an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Dr. Gupta earned his PhD in Biomedical Sciences and his MD from the University of California, San Francisco. After obtaining his MD, Dr. Gupta completed both his residency in internal medicine and his postdoctoral fellowship in hematology and oncology at Emory University where he was Chief Fellow in his final year.

Titles & Roles

Assistant Professor, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Medical Oncology/Hematology, 2015
Emory University School of Medicine
Residency, Internal Medicine, 2011
Emory University School of Medicine
Medical Education, 2009
University of California San Francisco

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2015
Hematology
American Board of Internal Medicine, 2015
Internal Medicine
American Board of Internal Medicine, 2013

Research

View Current Clinical Trials


A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) Phase III Conditions Multiple Myeloma, Newly Diagnosed Multiple Myeloma Location Winship Cancer Institute

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Phase
  
  III
- Conditions
  
  Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- Location
  
  Winship Cancer Institute

Publications

Title/Journal	Authors	Publication Date
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood	M Kaddoura, JE Wiedmeier-Nutor, VA Gupta, T Jelinek, B Ziccheddu, S Shivaram, H Tang, RW Owens, T Ševčíková, R Fonseca, MA Durante, BT Diamond, L Zhao, YX Zhu, CX Shi, SM Matulis, CS Mitsiades, CO Landgren, SZ Usmani, R Hajek, M Chesi, PL Bergsagel, E Braggio, LH Boise, R Fonseca, SK Kumar, F Maura, LB Baughn	01/02/2026
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience. Haematologica	L Cani, SA Scott, D Roberts, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, S Lonial, AK Nooka, JL Kaufman	09/04/2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract. Clinical lymphoma, myeloma & leukemia	SA Scott, DL Roberts, VA Gupta, NS Joseph, CC Hofmeister, MV Dhodapkar, S Lonial, AK Nooka, JL Kaufman	09/01/2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes. Clinical lymphoma, myeloma & leukemia	C Varga, M Robinson, V Gupta, CC Hofmeister, AK Nooka, JL Kaufman, MV Dhodapkar, S Lonial, S Borden, C Ferreri, B Paul, S Atrash, M Bhutani, PM Voorhees, NS Joseph	08/01/2025
Early CD4+ T-cell proliferative burst and chronic T-cell engagement impact myeloma outcomes following T-cell engager therapy. The Journal of clinical investigation	AM Duffy, A Goenka, MI Azeem, A Taz, SV Potdar, SA Scott, E Marin, JL Kaufman, CC Hofmeister, NS Joseph, VA Gupta, S Lonial, AK Nooka, MV Dhodapkar, KM Dhodapkar	07/31/2025
Another 1q bites the dust. Blood	VA Gupta, LH Boise	07/03/2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma. Blood advances	SV Potdar, S Kapadia, MI Azeem, R Radzievski, K Lakhani, NS Joseph, JL Kaufman, CC Hofmeister, VA Gupta, S Lonial, AK Nooka, KM Dhodapkar, MV Dhodapkar	05/27/2025
BCL2 inhibition for multiple myeloma and AL amyloidosis. British journal of haematology	L Cani, VA Gupta, JL Kaufman	05/01/2025
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood	R Nair, AH Vu, AK Freer, KS Bhatia, D Wang, MR Savani, SM Matulis, S Lonial, DL Jaye, LH Boise, SY Seo, TW Corson, AK Nooka, S Bhatt, SK McBrayer, VA Gupta, X Hu, BG Barwick, AR Reddi, M Shanmugam	02/13/2025
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma. Blood neoplasia	RP Dutta, S Thibaud, V Leshchenko, M Ram, DT Melnekoff, S Bhalla, P Restrepo, VA Gupta, BG Barwick, S Newman, J McCafferty, F Hantash, AK Nooka, HJ Cho, S Richard, C Rodriguez, A Rossi, L Sanchez, A Chari, LH Boise, S Jagannath, J Richter, S Parekh, A Laganà	12/01/2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients. Blood cancer journal	NS Joseph, JL Kaufman, VA Gupta, CC Hofmeister, MV Dhodapkar, LH Boise, SM DiCamillo, D Roberts, AK Nooka, S Lonial	09/13/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	12/20/2023
Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors. Cancer research communications	D Juarez, R Buono, SM Matulis, VA Gupta, M Duong, J Yudiono, M Paul, S Mallya, G Diep, P Hsin, A Lu, SM Suh, VM Dong, AW Roberts, JD Leverson, M Jalaluddin, Z Liu, OF Bueno, LH Boise, DA Fruman	12/08/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	08/01/2023
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias. Nature cancer	R de Matos Simoes, R Shirasaki, SL Downey-Kopyscinski, GM Matthews, BG Barwick, VA Gupta, D Dupéré-Richer, S Yamano, Y Hu, M Sheffer, E Dhimolea, O Dashevsky, S Gandolfi, K Ishiguro, RM Meyers, JG Bryan, NV Dharia, PJ Hengeveld, JB Brüggenthies, H Tang, AJ Aguirre, QL Sievers, BL Ebert, BJ Glassner, CJ Ott, JE Bradner, NP Kwiatkowski, D Auclair, J Levy, JJ Keats, RWJ Groen, NS Gray, AC Culhane, JM McFarland, JM Dempster, JD Licht, LH Boise, WC Hahn, F Vazquez, A Tsherniak, CS Mitsiades	05/01/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	02/20/2023
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. Science advances	A Sharma, R Nair, A Achreja, A Mittal, P Gupta, K Balakrishnan, CL Edgar, O Animasahun, B Dwivedi, BG Barwick, VA Gupta, SM Matulis, M Bhasin, S Lonial, AK Nooka, AP Wiita, LH Boise, D Nagrath, M Shanmugam	09/30/2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica	R Nair, V Subramaniam, BG Barwick, VA Gupta, SM Matulis, S Lonial, LH Boise, AK Nooka, K Muthumalaiappan, M Shanmugam	09/01/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	08/04/2022
It takes T to tango: immunotherapy in MM. Blood	VA Gupta, MV Dhodapkar	03/03/2022
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia	S Kunte, L Rybicki, A Viswabandya, R Tamari, A Bashey, A Keyzner, M Iqbal, MR Grunwald, B Dholaria, H Elmariah, M Ozga, A Singh, S Abedin, AE DeZern, RJ Jones, V Gupta, AT Gerds, T Jain	03/01/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	02/01/2022
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. Blood	CR Funk, S Wang, KZ Chen, A Waller, A Sharma, CL Edgar, VA Gupta, S Chandrakasan, JT Zoine, A Fedanov, SS Raikar, JL Koff, CR Flowers, S Coma, JA Pachter, S Ravindranathan, HT Spencer, M Shanmugam, EK Waller	01/27/2022
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	11/01/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	07/01/2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, KN Conneely, YC Lin, CC Hofmeister, AK Nooka, JJ Keats, S Lonial, PM Vertino, LH Boise	06/01/2021
Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. Molecular therapy oncolytics	J Ghose, A Dona, M Murtadha, EG Gunes, E Caserta, JY Yoo, L Russell, AC Jaime-Ramirez, BG Barwick, VA Gupta, JF Sanchez, DW Sborov, ST Rosen, A Krishnan, LH Boise, B Kaur, CC Hofmeister, F Pichiorri	03/26/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	03/01/2021
BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. Blood and lymphatic cancer : targets and therapy	VA Gupta, J Ackley, JL Kaufman, LH Boise	01/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	12/14/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	06/10/2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature communications	R Bajpai, A Sharma, A Achreja, CL Edgar, C Wei, AA Siddiqa, VA Gupta, SM Matulis, SK McBrayer, A Mittal, M Rupji, BG Barwick, S Lonial, AK Nooka, LH Boise, D Nagrath, M Shanmugam	03/06/2020
Approaches to Treating Multiple Myeloma, Now and Moving Forward. JCO oncology practice	VA Gupta, NS Joseph, AK Nooka	01/01/2020
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	11/25/2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer	AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, LH Boise, S Lonial	09/01/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	07/15/2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia	SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, LT Heffner, S Lonial, AK Nooka, JL Kaufman, LH Boise	05/01/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	04/23/2019
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	V Gupta, HE Kosiorek, A Mead, RB Klisovic, JP Galvin, D Berenzon, A Yacoub, A Viswabandya, RA Mesa, J Goldberg, L Price, ME Salama, RS Weinberg, R Rampal, N Farnoud, AC Dueck, JO Mascarenhas, R Hoffman	02/01/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	02/01/2019
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in immunology	BG Barwick, VA Gupta, PM Vertino, LH Boise	01/01/2019
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. The Lancet. Haematology	CN Harrison, AM Vannucchi, U Platzbecker, F Cervantes, V Gupta, D Lavie, F Passamonti, EF Winton, H Dong, J Kawashima, JD Maltzman, JJ Kiladjian, S Verstovsek	02/01/2018
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood	VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, S Lonial, LH Boise	04/06/2017
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer biology & therapy	KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, AK Nooka, JL Kaufman, S Lonial, LH Boise	07/02/2016
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia	SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, LH Boise	05/01/2016

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

5	One star One star One star One star One star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
5	One star One star One star One star One star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	12/30/2025	Impressed by everyone we met.
One star One star One star One star One star	12/05/2025	Dr Gupta is the best. He is very professional and along with that he is also caring. I really feel at ease when tell him about my concerns.
One star One star One star One star One star	12/03/2025	Dr Gupta was very thorough in explaining clinical trial standard of care progress and future plan.
One star One star One star One star One star	11/22/2025	Dr Gupta and his team at Emory are very caring, you can feel the level of expertise as soon as you walk in ! I feel very comfortable under his care. It matters when you have this level of care :)
One star One star One star One star One star	11/19/2025	Dr. Gupta is the best!
One star One star One star One star One star	11/14/2025	In person speaking was what I needed to gain better understanding of my treatments
One star One star One star One star One star	10/17/2025	Dr. Vikas Gupta always answers my questions and addresses my concerns.
One star One star One star One star One star	09/24/2025	Dr. Gupta is always considerate and patient with our questions.
One star One star One star One star One star	09/12/2025	Dr Gupta was excellent. Reviewed progress and results. Recommended benefits of getting a port . Answered all questions and facilitated understanding.
One star One star One star One star One star	09/10/2025	Dr. Gupta is very patient and has a great bedside manner. He listens carefully to our questions and provides clear, easy to understand responses. We appreciate that.
One star One star One star One star One star	08/27/2025	It's nice to have a doctor that knows what he's going to say when he walks in the door, but is always open to your questions and concerns and can address them in terms that you understand. I have great confidence in him, which is very comforting.
One star One star One star One star One star	08/27/2025	An all round positive visit.
One star One star One star One star One star	07/23/2025	The process was great
One star One star One star One star One star	07/03/2025	Dr Gupta did an excellent job of explaining things and answered all of our questions.
One star One star One star One star One star	07/02/2025	We appreciate Dr. Gupta's care and concern for us. He is very patient with all our questions.
One star One star One star One star One star	05/22/2025	Dr Gupta knew all the details concerning my visit but wanted to make sure that I was aware and expressed his concerns and talked to me about his thoughts and plans for future treatment
One star One star One star One star One star	04/23/2025	Good
One star One star One star One star One star	04/18/2025	Dr. Gupta was very engaged and compassionate during our discussion. We did not feel rushed at all and are grateful.
One star One star One star One star One star	03/20/2025	Dr. Gupta is always personable, supportive, and obviously very knowledgeable.
One star One star One star One star Empty star	03/04/2025	He explained I would say everything, but some were in the middle I had a information over load that was more me than the doctor
One star One star One star One star One star	01/29/2025	This was a second opinion, but the doctor explained things very well which gave us relief and hope.
One star One star One star One star One star	01/01/2025	Good
One star One star One star One star One star	12/08/2024	Dr. Vikas Gupta is an excellent listener making me feel cared for and respected.
One star One star One star One star One star	12/04/2024	Dr Gupta was excellent
One star One star One star One star One star	11/28/2024	We really appreciate Dr Gupta
One star One star One star One star One star	10/23/2024	We are truly confident that we are in the best hands with Dr. Vikas Gupta!
One star One star One star One star One star	09/04/2024	Meds were done rather quickly and received in a timely manner
One star One star One star One star One star	07/06/2024	Dr. Gupta was very thorough and detailed as he explained my cancer diagnosis and treatment options.
One star One star One star One star One star	06/20/2024	Dr. Gupta explained the process he was recommending and then asked if I had any concerns.
One star One star One star One star One star	05/15/2024	Dr. Gupta always answers any and all questions and listens.
One star One star One star One star One star	04/17/2024	Dr Gupta was empathetic, thorough, explained things in an understandable manner. He arranged a bone marrow biopsy while we were there, even though this was our first consult.
One star One star One star One star One star	03/20/2024	Dr. Gupta is an excellent lister and communicator.
One star One star One star One star One star	03/20/2024	Dr. Gupta is very attentive, listens to all concerns and updates. Answers all questions and explains treatment progress
One star One star One star One star One star	03/04/2024	Dr. Gupta is a very good, and caring Doctor.
One star One star One star One star One star	02/28/2024	Great service
One star One star One star One star One star	02/22/2024	Always listens, always takes time to throughly answer questions
One star One star One star One star One star	01/24/2024	Dr. Gupta always listens, carefully considers my questions and relays a well thought out response.
One star One star One star One star One star	01/17/2024	Best doctor I have ever had in my life wished he could be my primary care doc